Early-stage formation of an epigenetic field defect in a mouse colitis model, and non-essential roles of T-and B-cells in DNA methylation induction

Oncogene

Volumn 31, Issue 3, 2012, Pages 342-351

  Katsurano, M ^a   Niwa, T ^a   Yasui, Y ^b   Shigematsu, Y ^a   Yamashita, S ^a   Takeshima, H ^a   Lee, M S ^c   Kim, Y J ^c   Tanaka, T ^b   Ushijima, T ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c Yonsei University   (South Korea)

Author keywords

colon cancer; DNA methylation; epigenetics; inflammation; mouse

Indexed keywords

AZOXYMETHANE; DEXTRAN SULFATE; GAMMA INTERFERON RECEPTOR 1; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CARCINOGENICITY; CELL FUNCTION; CELL INFILTRATION; COLITIS; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; B-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; COLITIS; COLONIC NEOPLASMS; CPG ISLANDS; DEXTRAN SULFATE; DNA METHYLATION; EPIGENESIS, GENETIC; INTERFERON-GAMMA; INTERLEUKIN-1BETA; INTERLEUKIN-2; INTERLEUKIN-6; MALE; MICE; MICE, INBRED BALB C; MICE, SCID; NITRIC OXIDE SYNTHASE TYPE II; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 84855968457     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.241     Document Type: Article

References (51)

1. Araki Y, Sugihara H, Hattori T. (2006). In vitro effects of dextran sulfate sodium on a Caco-2 cell line and plausible mechanisms for dextran sulfate sodium-induced colitis. Oncol Rep 16: 1357-1362.
2. Autschbach F, Giese T, Gassler N, Sido B, Heuschen G, Heuschen U et al. (2002). Cytokine/chemokine messenger-RNA expression profiles in ulcerative colitis and Crohn's disease. Virchows Arch 441: 500-513. (Pubitemid 35430467)
3. Bosma GC, Custer RP, Bosma MJ. (1983). A severe combined immunodeficiency mutation in the mouse. Nature 301: 527-530. (Pubitemid 13160576)
4. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. (2003). A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 63: 1727-1730. (Pubitemid 36460827)
5. Cappello M, Keshav S, Prince C, Jewell DP, Gordon S. (1992). Detection of mRNAs for macrophage products in inflammatory bowel disease by in situ hybridisation. Gut 33: 1214-1219.
6. Cheng H, Bjerknes M, Amar J. (1984). Methods for the determination of epithelial cell kinetic parameters of human colonic epithelium isolated from surgical and biopsy specimens. Gastroenterology 86: 78-85. (Pubitemid 14177321)
7. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. (1994). Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107: 1643-1652. (Pubitemid 24357616)
8. Esteller M. (2008). Epigenetics in cancer. N Engl J Med 358: 1148-1159.
9. Fraga MF, Herranz M, Espada J, Ballestar E, Paz MF, Ropero S et al. (2004). A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res 64: 5527-5534. (Pubitemid 39095543)
10. Garrity-Park MM, Loftus Jr EV., Sandborn WJ, Bryant SC, Smyrk TC. (2010). Methylation Status of Genes in Non-Neoplastic Mucosa From Patients With Ulcerative Colitis-Associated Colorectal Cancer. Am J Gastroenterol.
11. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S et al. (2009). IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15: 103-113.
12. Hahn MA, Hahn T, Lee DH, Esworthy RS, Kim BW, Riggs AD et al. (2008). Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res 68: 10280-10289.
13. Hanada T, Kobayashi T, Chinen T, Saeki K, Takaki H, Koga K et al. (2006). IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J Exp Med 203: 1391-1397. (Pubitemid 43877600)
14. Hmadcha A, Bedoya FJ, Sobrino F, Pintado E. (1999). Methylationdependent gene silencing induced by interleukin 1beta via nitric oxide production. J Exp Med 190: 1595-1604.
15. Hodge DR, Xiao W, Clausen PA, Heidecker G, Szyf M, Farrar WL. (2001). Interleukin-6 regulation of the human DNA methyltransferase (HDNMT) gene in human erythroleukemia cells. J Biol Chem 276: 39508-39511.
16. Hsieh CJ, Klump B, Holzmann K, Borchard F, Gregor M, Porschen R. (1998). Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res 58: 3942-3945. (Pubitemid 28405652)
17. Hur K, Niwa T, Toyoda T, Tsukamoto T, Tatematsu M, Yang HK et al. (2011). Insufficient role of cell proliferation in aberrant DNA methylation induction and involvement of specific types of inflammation. Carcinogenesis 32: 35-41.
18. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA. (2001). Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 61: 3573-3577. (Pubitemid 32694963)
19. Ito R, Shin-Ya M, Kishida T, Urano A, Takada R, Sakagami J et al. (2006). Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol 146: 330-338. (Pubitemid 44581349)
20. Jones PA, Baylin SB. (2007). The epigenomics of cancer. Cell 128: 683-692. (Pubitemid 46273572)
21. Kass DH, Kim J, Rao A, Deininger PL. (1997). Evolution of B2 repeats: the muroid explosion. Genetica 99: 1-13. (Pubitemid 27284780)
22. Keshet I, Schlesinger Y, Farkash S, Rand E, Hecht M, Segal E et al. (2006). Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet 38: 149-153. (Pubitemid 43177227)
23. Kim YH, Lee HC, Kim SY, Yeom YI, Ryu KJ, Min BH et al. (2011). Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations. Ann Surg Oncol (doi:10.1245/s10434- 011-1573-y).
24. Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. (2000). Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis-A comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 32: 970-979.
25. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. (1993). Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274. (Pubitemid 23320290)
26. Li Y, de Haar C, Chen M, Deuring J, Gerrits MM, Smits R et al. (2009). Disease-related expression of the IL-6/STAT3/SOCS3 signaling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 59: 227-235.
27. Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D. (1990). Role of interleukin 1 in inflammatory bowel disease-enhanced production during active disease. Gut 31: 686-689.
28. Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M et al. (2006). High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 12: 989-995. (Pubitemid 43259882)
29. McLaughlan JM, Seth R, Vautier G, Robins RA, Scott BB, Hawkey CJ et al. (1997). Interleukin-8 and inducible nitric oxide synthase mRNA levels in inflammatory bowel disease at first presentation. J Pathol 181: 87-92. (Pubitemid 27099779)
30. Nagao M, Ochiai M, Okochi E, Ushijima T, Sugimura T. (2001). LacI transgenic animal study: relationships among DNA-adduct levels, mutant frequencies and cancer incidences. Mutat Res 477: 119-124. (Pubitemid 32480195)
31. Nakajima T, Maekita T, Oda I, Gotoda T, Yamamoto S, Umemura S et al. (2006). Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Biomarkers Prev 15: 2317-2321. (Pubitemid 44877064)
32. Ni J, Chen SF, Hollander D. (1996). Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes. Gut 39: 234-241. (Pubitemid 26276001)
33. Niwa T, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T et al. (2010). Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res 70: 1430-1440.
34. Niwa T, Yamashita S, Tsukamoto T, Kuramoto T, Nomoto T, Wakazono K et al. (2005). Whole-genome analyses of loss of heterozygosity and methylation analysis of four tumor-suppressor genes in N-methyl-N'-nitro-N-nitrosoguanidine- induced rat stomach carcinomas. Cancer Sci 96: 409-413. (Pubitemid 41179742)
35. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S et al. (2008). Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118: 560-570. (Pubitemid 351206546)
36. Qian X, Huang C, Cho CH, Hui WM, Rashid A, Chan AO. (2008). E-cadherin promoter hypermethylation induced by interleukin-1beta treatment or H. pylori infection in human gastric cancer cell lines. Cancer Lett 263: 107-113.
37. Riggs AD, Xiong Z. (2004). Methylation and epigenetic fidelity. Proc Natl Acad Sci USA 101: 4-5. (Pubitemid 38084192)
38. Rosenberg DW, Giardina C, Tanaka T. (2009). Mouse models for the study of colon carcinogenesis. Carcinogenesis 30: 183-196.
39. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. (1993). Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75: 253-261. (Pubitemid 23320289)
40. Schulmann K, Sterian A, Berki A, Yin J, Sato F, Xu Y et al. (2005). Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett'sassociated neoplastic progression and predicts progression risk. Oncogene 24: 4138-4148. (Pubitemid 40897058)
41. Takeshima H, Yamashita S, Shimazu T, Niwa T, Ushijima T. (2009). The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands. Genome Res 19: 1974-1982.
42. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. (2003). A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 94: 965-973. (Pubitemid 37508979)
43. Taniwaki K, Fukamachi H, Komori K, Ohtake Y, Nonaka T, Sakamoto T et al. (2007). Stroma-derived matrix metalloproteinase (MMP)-2 promotes membrane type 1-MMP-dependent tumor growth in mice. Cancer Res 67: 4311-4319. (Pubitemid 46815079)
44. Ushijima T. (2005). Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 5: 223-231. (Pubitemid 40314953)
45. Ushijima T. (2007). Epigenetic field for cancerization. J Biochem Mol Biol 40: 142-150. (Pubitemid 46515191)
46. Ushijima T, Okochi-Takada E. (2005). Aberrant methylations in cancer cells: where do they come from? Cancer Sci 96: 206-211. (Pubitemid 40767056)
47. Vuillemenot BR, Pulling LC, Palmisano WA, Hutt JA, Belinsky SA. (2004). Carcinogen exposure differentially modulates RAR-beta promoter hypermethylation, an early and frequent event in mouse lung carcinogenesis. Carcinogenesis 25: 623-629. (Pubitemid 38499951)
48. Wang D, Dubois RN. (2010). The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 29: 781-788.
49. Yamashita S, Hosoya K, Gyobu K, Takeshima H, Ushijima T. (2009). Development of a novel output value for quantitative assessment in methylated DNA immunoprecipitation-CpG island microarray analysis. DNA Res 16: 275-286.
50. Yamashita S, Takahashi S, McDonell N, Watanabe N, Niwa T, Hosoya K et al. (2008). Methylation silencing of transforming growth factor-beta receptor type II in rat prostate cancers. Cancer Res 68: 2112-2121. (Pubitemid 351521783)
51. Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu YZ et al. (2005). Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet 37: 265-274. (Pubitemid 41716253)